期刊文献+

利拉鲁肽激活糖尿病大鼠肾脏内皮源性一氧化氮合酶活性降低尿白蛋白排泄的研究 被引量:13

Liraglutide reduces urinary albumin excretion by activating endothelial nitric oxide synthase of kidney in diabetic rats
原文传递
导出
摘要 目的探讨利拉鲁肽对糖尿病大鼠24hUAlb排泄的影响及机制。方法将30只大鼠分为正常对照(NC)组、糖尿病(DM)组和利拉鲁肽(DM+L)组。检测各组给药前后血肌酐(Scr)、BUN和24hUAlb。HE、PAS染色观察肾脏形态学改变;Western blot检测肾脏GLP-1受体(GLP-1R)、内皮源性一氧化氮合酶(eNOS)、p-eNOS表达;ELISA检测eNOS活性。结果与NC组相比,DM组Scr、BUN、24hUAlb升高,肾脏eNOS表达比较差异无统计学意义,GLP-1R、p-eNOS表达及eNOS活性降低(P<0.01)。与DM组相比,DM+L组Scr、BUN、24hUAlb降低,肾脏GLP-1R、p-eNOS表达及eNOS活性升高(P<0.05或P<0.01)。结论利拉鲁肽可上调糖尿病大鼠肾脏GLP-1R表达,提高肾小球血管内皮细胞eNOS活性,减少糖尿病大鼠UAlb排泄。 Objective To explore the effects of liraglutide on 24 hUAlb excretion in diabetic rats and its potential mechanism. Methods 30 rats were divided into normal control(NC),diabetes(DM)and liraglutide treated DM(DM+L)group.Serum creatinine(Scr),BUN and 24 hUAlb were measured before and after treatment.Renal morphological changes were evaluated by HE and PAS staining.Protein expressions of GLP-1receptor(GLP-1R),endothelial nitric oxide synthase(eNOS),and p-eNOS were detected by Western blot.The eNOS activity was determined by ELISA. Results Compared to NC group,DM group and DM+L group showed that Scr,BUN,24 hUAlb excretion were significantly increased and that specimen of renal biopsy showed inflammatory cells infiltration,fibrosis and even glomerular sclerosis.There were no significant differences in eNOS expression between two groups,however the expression of GLP-1R,p-eNOS and eNOS activity were significantly decreased(P<0.01).Compared with DM group,DM+L group showed that Scr,BUN and 24 hUAlb excretion were significantly decreased,and that the expression of GLP-1R,p-eNOS and eNOS activity were significantly increased(P<0.05 or P<0.01). Conclusion Liraglutide could reduce urinary albumin excretion through upregulating the expression of GLP-1Rand then activating eNOS in kidney.
出处 《中国糖尿病杂志》 CAS CSCD 北大核心 2014年第9期846-849,共4页 Chinese Journal of Diabetes
关键词 利拉鲁肽 糖尿病肾病 GLP-1受体 内皮源性一氧化氮合酶 尿白蛋白排泄 Liraglutide Diabetic nephropathy(DN) GLP-1receptor(GLP-1R) Endothelial nitric oxide synthase(eNOS) Urinary albumin(UAlb)excretion
  • 相关文献

参考文献12

  • 1Nakagawa T,Sato W,Sautin YY,et al.Uncoupling of vascular endothelial growth factor with nitric xxide as a mechanism for diabetic vasculopathy.J Am Soc Nephrol,2006,17:736-745.
  • 2Faria AM,Papadimitriou A,Silva KC,et al.Uncoupling endothelial nitric oxide synthase is ameliorated by green tea in ex perimental diabetes by re-establishing tetrahydrobiopterin levels.Diabetes,2012,61:1838-1847.
  • 3Kim M,Platt MJ,Shibasaki T,et al.G1P-1 receptor activation and Epac2 link atrial natriuretic peptide secretion to control of blood pressure.Nat Med,2013,19:567-575.
  • 4杨文英.人GLP-1类似物利拉鲁肽的最新研究进展[J].中华内分泌代谢杂志,2010,26(9):840-843. 被引量:32
  • 5Sturis J,Gotfredse CF,R(o)mer J,et al.GLP-1 derivative liraglutide in rats with β-cell deficiencies:influence of metabolic state on β-cell mass dynamics.Br J Pharmacol,2003,140:123-132.
  • 6Tian S,Gan Y,Li J,et al.Imbalance of glomerular VEGF-NO axis in diabetic rats:prevention by chronic therapy with propyl gallate.J Nephrol,2011,24:499-506.
  • 7Gaspari T,Welungoda I,Widdop RE,et al.The GLP-1 receptor agonist liraglutide inhibits progression of vascular disease via effects onatherogenesis,plaque stability and endothelial function in an ApoE(-/-) mouse model.Diab Vasc Dis Res,2013,10:353-360.
  • 8孟凡东,李伟.利拉鲁肽对肿瘤坏死因子α刺激下大鼠肾小球系膜细胞纤溶酶原激活物抑制物1和胞间黏附分子1表达的影响[J].中华肾脏病杂志,2012,28(9):715-719. 被引量:1
  • 9Verspohl EJ.Novel therapeutics for type 2 diabetes:incretin hormone mimetics (glucagon-like peptide-1 receptor agonists) and dipeptidyl peptidase-4 inhibitors.Pharmacol Ther,2009,124:113-138.
  • 10Balakumar P,Chakkarwar VA,Krishan P,et al.Vascular endothelial dysfunction:a tug of war in diabetic nephropathy? Biomed Pharmacot her,2009,63:171-179.

二级参考文献47

  • 1潘长玉,田慧,刘国良,李秀钧,傅祖植,陈家伟,暨亚洲糖尿病管理中国协作组.中国城市中心医院糖尿病健康管理调查[J].中华内分泌代谢杂志,2004,20(5):420-424. 被引量:193
  • 2Pan C,Yang W,Jia W,et al.Management of Chinese patients with type 2 diabetes,1998-2006:the Diabcare-China surveys.Curr Med Res Opin,2009,25:39-45.
  • 3Salehi M,Aulinger BA,D'Alessio DA.Targeting beta-cell mass in type 2 diabetes:promise and limitations of new drugs based on incretins.Endocr Rev,2008,29:367-379.
  • 4Russell-Jones D.Molecular,pharmacological and clinical aspects of liraglutide,a once-daily human GLP-1 analogue.Mol Cell Endocrinol,2009,297:137-140.
  • 5Knudsen LB,Knudsen SM,Wilken M,et al.Plasma protein binding of NN2211,a long-acting derivative of GLP-1,is important for its efficacy.Diabetes,2003,52:A321 -A322.
  • 6Elbrφnd B,Jakobsen G,Larsen S,et al.Pharmacokinetics,pharmacodynamics,safety,and tolerability of a single-dose of NN2211,a long-acting glucagon-like peptide 1 derivative,in healthy male subjects.Diabetes Care,2002,25:1398-1404.
  • 7Knudsen LB,Tang-christensen M,Jelsing J,et al.Liraglutide:short-lived effect on gastric emptying-long-lasting effects on body weight.Diabetes,2010,59 (suppl 1):591 -P.
  • 8Vrang N,Jelsing J,Raun K,et al.Liraglutide regulates key hypothalamic appetite-related signals in diet-Induced obese rats.Diabetes,2010,59 (suppl 1):583-P.
  • 9Raun K,Vrang N,Jelsing J,et al.GLP-1 analog liraglutide activates brainstem and hypothalamic neurons involved in appetite regulation.Diabetes,2010,59 (suppl 1):584-P.
  • 10Simpson RW,Liu HB,Gaspari T,et al.Liraglutide inhibits endothelial cell dysfunction and reduces expression of adhesion molecules associated with atherogenesis.Diabetes,2010,59 (suppl 1):595-P.

共引文献31

同被引文献64

  • 1常洁,姜宗培,余学清.氧化应激及其在糖尿病肾病中的作用[J].国际内科学杂志,2007,34(2):105-108. 被引量:25
  • 2Jonas JC,Bensellam M,Duprez J,et al.Glucose regulation of islet stress responses and beta-cell failure in type 2 diabetes[J].Diabetes Obes Metab,2009,11(Suppl 4):65.
  • 3Augeri DJ,Robl JA,Betebenner DA,et al.Discovery and preclinical profile of saxagliptin(BMS-477118):a highly potent,long-acting,orally active dipeptidyl peptidaseⅣinhibitor for the treatment of type 2 diabetes[J].J Med Chem,2005,48(15):5025.
  • 4Zhao G,Taunk PC,Magnin DR,et al.Diprolyl nitriles as potent dipeptidyl peptidase IV inhibitors[J].Bioorg Med Chem Lett,2005,15(18):3992.
  • 5Alena A.Possibilities of therapy GLP1 RA for diabetics with nephropathy[J].Vnitr Lek,2015;61(4):312-5.
  • 6Silva MA,Cau SB,Lopes RA,et al.Mineralocorticoid receptor blockade prevents vascular remodelling in a rodent model of type 2diabetes mellitus[J].Clin Sci(Lond),2015,129(7):533-545.
  • 7Talebpour M,Talebpour A,Barzin G,et al.Effects of laparoscopic gastric plication(LGP)in patients with type 2 diabetes,one year follow-up[J].J Diabetes Metab Disord,2015,14:60.
  • 8Mosley JF 2nd,Smith L,Everton E,et al.Sodium-Glucose Linked Transporter 2(SGLT2)Inhibitors in the Management of Type-2Diabetes:A Drug Class Overview[J].P T,2015,40(7):451-462.
  • 9杨文英.人GLP-1类似物利拉鲁肽的最新研究进展[J].中华内分泌代谢杂志,2010,26(9):840-843. 被引量:32
  • 10魏盈盈,王玉萍,徐蓉,杨雁,杜光.普通胰岛素与诺和锐治疗糖尿病酮症酸中毒疗效比较[J].中国医院药学杂志,2010,30(21):1837-1839. 被引量:9

引证文献13

二级引证文献60

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部